Aims: More and more people with diabetes (PwD) are paying attention to the waste associated with new technologies and want more sustainable concepts for waste prevention and a positive ecological footprint. So far, there are little results on the importance people with diabetes attach to the issue of sustainability and environmental compatibility. In an online survey, we wanted to determine the extent of these wishes and ecological needs of PwD.

Methods: PwD in Germany were asked via online surveys (2.417 PwD; 47.5% female, 57.8% type 1 diabetes (T1D) , 20.7% type 2 diabetes (T2D) , 19.0% parents of children with diabetes; Ø 47.7 years) .

Results: For more than half of all respondents, the topic of packaging waste is important (54.5%) , two out of three respondents say they would like to see more reusable utensils in diabetes therapy (67.1%) . However, the amount of packaging waste in diabetes technologies does not seem to be a decision criterion for most PwD when selecting modern technologies - this is only significant for 15% (TSD 21,9%) . Overall, there were only slight differences between the groups of PwD.

Conclusions: Ecological aspects are becoming increasingly important in diabetes therapy: most PwD are concerned about the issue of packaging waste in diabetes technologies and would like to see more recyclable utensils for their diabetes therapy. Although the number of respondents who consider the amount of packaging waste to be a decisive criterion for the choice of a diabetes technology is low - among people with type 2 diabetes, however, this is already around one in five persons.


L.Heinemann: Board Member; Lifecare, Inc., Consultant; Becton, Dickinson and Company, Roche Diabetes Care, Stock/Shareholder; Profil Institut für Stoffwechselforschung GmbH, Science Consulting in Diabetes GmbH. D.Ehrmann: Advisory Panel; Dexcom, Inc., Consultant; mySugr, Roche Diabetes Care, Speaker's Bureau; Berlin-Chemie AG, Dexcom, Inc. T.Roos: None. N.Hermanns: Advisory Panel; Abbott Diabetes, Research Support; Becton, Dickinson and Company, Roche Diagnostics, Speaker's Bureau; Berlin-Chemie AG, Novo Nordisk, Sanofi. B.Kulzer: Advisory Panel; Bayer AG, Bayer AG, Becton, Dickinson and Company, Becton, Dickinson and Company, Berlin-Chemie AG, Berlin-Chemie AG, Dexcom, Inc., Dexcom, Inc., Insulet Corporation, Novo Nordisk, Roche Diabetes Care, Sanofi, Sanofi-Aventis Deutschland GmbH, Research Support; Novo Nordisk, Roche Diabetes Care.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at